Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a phase 3 clinical trial.

Adult height deficit seen in Turner syndrome (TS) originates, in part, from growth retardation in utero and throughout the first 3 years of life.

Who Took Part

By PubMed's age tags, the people studied were infants and young children, women only.

How the Study Was Run

The researchers set it up as an open-label and multicenter study.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

The main outcome measure was change in height SDS (H-SDS).

Other measures included changes in height velocity SDS, IGF1 levels and glucose metabolism.

What Was Measured

PubMed files the paper under topics including Age Determination by Skeleton, Blood Cell Count, Blood Glucose, Body Height, Carbohydrate Metabolism, Glycated Hemoglobin and Growth.

What This Means in Plain Language

The paper is an open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.